Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001601830-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-10 | 2026-02-06 | RXRX | Taylor Ben R | CFO | A - Grant | $0.00 | +470.5K | 1.23M | +62% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | Taylor Ben R | CFO | F - Tax | $3.98 | -11.4K | 1.22M | -0.9% | -$45.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-06 | A | A | 446,279 | $0.00 | 1,207,829 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-02-06 | A | A | 24,254 | $0.00 | 1,232,083 | D | — | — | |
| 3 | Common | Class A Common Stock | 2026-02-06 | F | D | 11,400 | $3.98 | 1,220,683 | D | — | — |